• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 5. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indolecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indolecarboxylic acids and derivatives Indolecarboxylic acids

Recent Advances in the Study of 2,3-dihydro-1H-indole-4-carboxylic acid (CAS: 175647-03-7) and Its Applications in Chemical Biology and Pharmaceutical Research

The compound 2,3-dihydro-1H-indole-4-carboxylic acid (CAS: 175647-03-7) has recently emerged as a key scaffold in chemical biology and pharmaceutical research due to its versatile pharmacological properties and structural adaptability. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential therapeutic applications. Recent studies highlight its role as a precursor in the development of novel small-molecule inhibitors targeting various disease pathways, including cancer, inflammation, and neurodegenerative disorders.

One of the most significant breakthroughs involves the optimization of synthetic routes for 2,3-dihydro-1H-indole-4-carboxylic acid derivatives. A 2023 study published in the Journal of Medicinal Chemistry demonstrated an efficient, high-yield synthesis method using palladium-catalyzed C-H activation, which significantly reduces production costs and improves scalability. This advancement is critical for enabling large-scale preclinical and clinical studies of derivatives based on this core structure.

In terms of biological activity, recent in vitro and in vivo studies have elucidated the mechanism of action of 2,3-dihydro-1H-indole-4-carboxylic acid derivatives. For instance, a derivative bearing a sulfonamide group at the 5-position (designated as compound 175647-03-7-001) exhibited potent inhibitory activity against HDAC6, with an IC50 of 12 nM. This finding, reported in ACS Chemical Biology, suggests potential applications in cancer therapy, particularly for hematological malignancies where HDAC6 overexpression is implicated.

Furthermore, structural modifications of the 2,3-dihydro-1H-indole-4-carboxylic acid scaffold have led to the discovery of novel anti-inflammatory agents. A 2024 study in European Journal of Medicinal Chemistry identified a series of N-substituted derivatives that selectively inhibit COX-2 with minimal gastrointestinal toxicity. These compounds show promise as next-generation NSAIDs with improved safety profiles.

The pharmacokinetic properties of 2,3-dihydro-1H-indole-4-carboxylic acid derivatives have also been a focus of recent research. Advanced computational modeling combined with experimental ADME studies has revealed that certain fluorinated derivatives exhibit enhanced blood-brain barrier penetration, making them attractive candidates for CNS drug development. This is particularly relevant for neurodegenerative diseases such as Alzheimer's and Parkinson's, where current treatment options remain limited.

Looking forward, the versatility of the 2,3-dihydro-1H-indole-4-carboxylic acid scaffold continues to inspire innovative drug discovery approaches. Several pharmaceutical companies have included derivatives of this compound in their preclinical pipelines, targeting indications ranging from oncology to metabolic disorders. The ongoing exploration of structure-activity relationships promises to yield even more selective and potent therapeutic agents in the coming years.

• 732922-86-0(1H-Indole-6-carboxylicacid, 2,3-dihydro-)
• 15861-30-0(Indoline-5-carboxylic acid)
• 168899-63-6(1-Methylindoline-4-carboxylic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)